Dotamtate Pb-212
- Generic Name
- Dotamtate Pb-212
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C65H91N17O16PbS2
- CAS Number
- -
- Unique Ingredient Identifier
- E9N7QV53AK
- Associated Conditions
- -
- Associated Therapies
- -
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Radiomedix, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT05153772
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Radiomedix, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03466216
- Locations
- 🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath